Health Care·Biotechnology·$2.6B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.43 | N/A | -2.38% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.43 | N/A | -2.38% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed a cautious outlook without offering specific guidance. They emphasized ongoing efforts in their development pipeline.
Management did not provide specific guidance for future quarters.
The focus remains on advancing pipeline projects.
Celldex Therapeutics reported a loss per share that was slightly worse than expected, contributing to a minor decline in stock price. The lack of revenue figures and guidance may raise concerns among investors about the company's near-term prospects. The stock's reaction reflects uncertainty in the market regarding the company's future performance.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
DT MIDSTREAM INC
Feb 25, 2022